| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/22/2014 | US8785156 TLE3 as a marker for chemotherapy |
| 07/22/2014 | US8785128 Genetic diagnosis of hepatic steatosis |
| 07/22/2014 | US8784909 Mud mask with real tea leaf and method for making the same |
| 07/22/2014 | US8784899 Compositions and methods for cancer treatment |
| 07/22/2014 | US8784893 Polymer formulations for delivery of bioactive agents |
| 07/22/2014 | US8784892 Method and composition for burned skin |
| 07/22/2014 | US8784888 Controlled release and taste masking oral pharmaceutical composition |
| 07/22/2014 | US8784887 Pharmaceutical preparation of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide |
| 07/22/2014 | US8784885 Controlled release preparation |
| 07/22/2014 | US8784882 Controlled release delivery system for nasal applications and method of treatment |
| 07/22/2014 | US8784880 Titratable dosage transdermal delivery system |
| 07/22/2014 | US8784879 Transdermal administration of tamsulosin |
| 07/22/2014 | US8784878 Transdermal delivery rate control using amorphous pharmaceutical compositions |
| 07/22/2014 | US8784874 Multi-layer transdermal drug delivery device |
| 07/22/2014 | US8784873 Use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly |
| 07/22/2014 | US8784872 Formulation for decreasing tobacco, alcohol, drug or food consumption |
| 07/22/2014 | US8784869 Controlled release delivery system for nasal applications and methods of treatment |
| 07/22/2014 | US8784867 Contact lenses containing carotenoid and method for making same |
| 07/22/2014 | US8784862 Compounds and method for coating surfaces in a hemocompatible manner |
| 07/22/2014 | US8784857 Articles incorporating absorbent polymer and ceragenin compound |
| 07/22/2014 | US8784852 Topical skin care composition |
| 07/22/2014 | US8784849 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers |
| 07/22/2014 | US8784844 Arabinogalactan for enhancing the adaptive immune response |
| 07/22/2014 | US8784840 Method for screening modulators of apoptosis |
| 07/22/2014 | US8784812 Methods for treating autoimmune diseases using a TACI-Ig fusion molecule |
| 07/22/2014 | US8784796 Vaccine immunotherapy for treating hepatocellular cancer in immune suppressed patients |
| 07/22/2014 | US8784795 Methods for determining personalized treatment compositions for prostate cancer and breast cancer |
| 07/22/2014 | US8784793 Conformable solvent-based bandage and coating material |
| 07/22/2014 | US8784792 Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease |
| 07/22/2014 | US8784791 Method for preparing water-soluble polymer derivatives bearing an N-succinimidyl ester |
| 07/22/2014 | US8784790 Method for treating chronic wounds with an extracellular polymeric substance solvating system |
| 07/22/2014 | US8784789 Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| 07/22/2014 | US8784782 Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
| 07/22/2014 | US8784780 High oil-content emollient aerosol foam compositions |
| 07/22/2014 | US8784385 Frozen piercing implements and methods for piercing a substrate |
| 07/22/2014 | CA2762960C Recrystallization processes for obtaining anhydrous optically active lansoprazole |
| 07/22/2014 | CA2749218C Hydroxy-methyl isoxazole derivatives as gaba a modulators |
| 07/22/2014 | CA2748979C Sodium stearoyl-2-lactylate derivatives as an animal feed additive for improving fat utilization efficiency |
| 07/22/2014 | CA2748765C Compounds, compositions, and methods for preventing metastasis of cancer cells |
| 07/22/2014 | CA2735120C Compounds, compositions and methods for the treatment of .beta.-amyloid diseases and synucleinopathies |
| 07/22/2014 | CA2662320C Bcl inhibitors treating platelet excess |
| 07/22/2014 | CA2660572C Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof |
| 07/22/2014 | CA2656961C A topical anaesthetic composition |
| 07/22/2014 | CA2656549C Medicament for the enhancement of cognitive function and neuroprotection |
| 07/22/2014 | CA2655676C Phenylacetic acid derivatives |
| 07/22/2014 | CA2654218C Process for the preparation of pure irbesartan |
| 07/22/2014 | CA2649459C Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid |
| 07/22/2014 | CA2641396C Process for manufacturing entacapone |
| 07/22/2014 | CA2632910C Biphenyl derivatives as selective agonists of gamma rar receptor |
| 07/22/2014 | CA2610025C Scopolamine for the treatment of depression and anxiety |
| 07/22/2014 | CA2606510C Pharmaceutical preparation for oral administration comprising an imide compound |
| 07/22/2014 | CA2605699C Bioabsorbable device having composite structure for accelerating degradation |
| 07/22/2014 | CA2589438C Treatment of inflammatory bowel disease |
| 07/22/2014 | CA2584489C Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| 07/22/2014 | CA2582766C Isomigrastatin analogs in the treatment of cancer |
| 07/22/2014 | CA2573144C Methods for treating conditions associated with masp-2 dependent complement activation |
| 07/22/2014 | CA2555058C N-deacetylthiocolchicine derivatives, their use and pharmaceutical formulations containing them |
| 07/22/2014 | CA2549509C Composition for improving skin, hair and coat health containing flavanones |
| 07/22/2014 | CA2538527C Fluid medication delivery device |
| 07/22/2014 | CA2533423C Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer |
| 07/22/2014 | CA2524883C Potassium-chloride cotransporter kcc2 modulation for treatment of pain |
| 07/22/2014 | CA2412845C Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 07/22/2014 | CA2405299C Method of treatment using ligand-immunogen conjugates |
| 07/21/2014 | CA2803215A1 Compositions and methods related to prostate cancer |
| 07/17/2014 | WO2014110580A1 Honey nasal rinse |
| 07/17/2014 | WO2014110574A1 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| 07/17/2014 | WO2014110558A1 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| 07/17/2014 | WO2014110555A1 Compositions and methods for treating cancer |
| 07/17/2014 | WO2014110551A1 Antioxidant flavonoid derivatives |
| 07/17/2014 | WO2014110466A1 Pyridine compounds used as pi3 kinase inhibitors |
| 07/17/2014 | WO2014110454A1 Stabilized compositions comprising hyaluronic acid |
| 07/17/2014 | WO2014110451A1 Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders |
| 07/17/2014 | WO2014110443A1 Methods of treating pancreatic cancer |
| 07/17/2014 | WO2014110442A1 Beta-lactamase inhibitors |
| 07/17/2014 | WO2014110408A1 Method for treating cancer based on mutation status of k-ras |
| 07/17/2014 | WO2014110345A1 Method for treating cancer based on level of a nucleoside transporter |
| 07/17/2014 | WO2014110344A1 Meglumine salt forms of 2-((1 r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors |
| 07/17/2014 | WO2014110305A1 Vitamins c and k for treating polycystic diseases |
| 07/17/2014 | WO2014110298A1 5-membered heteroaryls and their use as antiviral agents |
| 07/17/2014 | WO2014110297A1 (hetero) arylacetamide derivatives as antiretroviral agents |
| 07/17/2014 | WO2014110277A1 Methods of treating developmental and personality disorders |
| 07/17/2014 | WO2014110270A1 Stable parenteral dnj compositions |
| 07/17/2014 | WO2014110261A1 Cyp450 lipid metabolites reduce inflammation and angiogenesis |
| 07/17/2014 | WO2014110259A1 Solid forms of a jak inhibitor |
| 07/17/2014 | WO2014110248A1 Controlled release formulations of lorazepam |
| 07/17/2014 | WO2014110245A1 Sustained release formulations of lorazepam |
| 07/17/2014 | WO2014110234A1 Methods of treating developmental and personality disorders |
| 07/17/2014 | WO2014110200A1 Non-selective kinase inhibitors |
| 07/17/2014 | WO2014110198A2 Therapeutic indications of kinase inhibitors |
| 07/17/2014 | WO2014110189A1 Deuterated momelotinib |
| 07/17/2014 | WO2014110177A2 Small molecules that promote skin regeneration |
| 07/17/2014 | WO2014110165A1 Treatment of graft-versus-host disease disorders using rar antagonists |
| 07/17/2014 | WO2014110154A1 Methods and comp0stions for treatment of demyelinating diseases |
| 07/17/2014 | WO2014110114A1 Irak inhibitors and uses thereof |
| 07/17/2014 | WO2014110103A1 Biphenyl-ethyl-pyrrolidine derivatives as histamine h3 receptor modulators for the treatment of cognitive disorders |
| 07/17/2014 | WO2014110066A1 Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis c |
| 07/17/2014 | WO2014110065A1 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS |
| 07/17/2014 | WO2014110036A1 Ship1 modulators and methods related thereto |
| 07/17/2014 | WO2014110035A1 Odor suppression of volatile organic analgesic compounds and method of use |
| 07/17/2014 | WO2014110000A1 Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain |